Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy

Chimeric antigen receptor (CAR) T cell therapy can achieve outstanding response rates in heavily pretreated patients with hematological malignancies. However, relapses occur and they limit the efficacy of this promising treatment approach. The cellular composition and immunophenotype of the administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Stock, Sophia, Schmitt, Michael, Sellner, Leopold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940894/
https://www.ncbi.nlm.nih.gov/pubmed/31835562
http://dx.doi.org/10.3390/ijms20246223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940894/
https://www.ncbi.nlm.nih.gov/pubmed/31835562
http://dx.doi.org/10.3390/ijms20246223

Ejemplares similares